retatrutide parkinson's clinical trial First phase 3 data for are here folks. This drug is a barn burner. This was only 68 weeks and was geared towards osteoarthritis of the knee. Massive pain improvements and retatrutide parkinson clinical trial 💊

In the prescription medication industry, there are single glucagon-like peptide-1 (GLP-1) receptor agonist options (weight loss injections) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist options that are marketed for the treatment of diabetes, obesity, and weight management solutions

Because these medications actively modulate metabolic and digestive systems, they are not suitable for all patients

The inpatient admission copay will be $425 per day

Ambery P, Parker VE, Sumvoll M et al (2018) MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomized, controlled, double-blind, ascending dose and phase 2A study